Bionano Genomics (BNGO) Other Non-Current Liabilities (2017 - 2024)

Bionano Genomics has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $5.8 million for Q2 2024.

• Other Non-Current Liabilities for Q2 2024 came in at $5.8 million, down 60.37% year-over-year; the trailing twelve-month figure through Jun 2024 was $5.8 million (down 60.37% YoY), and the FY2023 annual result was $10.9 million, down 16.04% from the prior year.
• Other Non-Current Liabilities came in at $5.8 million for Q2 2024 at Bionano Genomics, down from $10.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $14.9 million in Q3 2023 to a low of $75000.0 in Q3 2020.
• The 5-year median for Other Non-Current Liabilities is $10.6 million (2023), against an average of $9.2 million.
• Across the five-year window, Other Non-Current Liabilities surged 209.33% in 2021 and plunged 60.37% in 2024, its largest moves.
• Bionano Genomics' Other Non-Current Liabilities stood at $75000.0 in 2020, then soared by 11988.0% to $9.1 million in 2021, then surged by 43.06% to $13.0 million in 2022, then declined by 16.04% to $10.9 million in 2023, then slumped by 46.98% to $5.8 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $5.8 million (Q2 2024), $10.2 million (Q1 2024), and $10.9 million (Q4 2023), per Business Quant data.